BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)BALA CYNWYD, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
May 2025 Industrial Manufacturing Near March 2025 Levels with 146 New Planned Capital Projects Heading into SummerJACKSONVILLE, Fla., June 17, 2025 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads announced today the May 2025 results for its new planned capital project spending report for the Industrial Manufacturing industry. The report reveals a continuation of robust activity. The Firm, which tracks North American planned industrial capital project activity including facility expansions, new plant construction, and significant equipment modernization projects, confirmed 146 new projects in the Industrial Manufacturing sector for May. - News from Industrial SalesLeads Inc, issued by Send2Press Newswire
Bila Solar’s Indiana Factory Commences Production of Domestic Solar Panels, Strengthening U.S. Clean Energy Manufacturing at Key Policy MomentBehind-the-scenes video captures this milestone for American solar — creating local jobs and reinforcing why federal support for clean energy matters
Ireland: America’s Gateway to Europe – The $2 Trillion Investment StoryIreland has emerged as the undisputed champion in attracting U.S. foreign direct investment, hosting an extraordinary €897 billion (over $1 trillion) in American capital. This massive investment flow has transformed the small island nation into America's premier European platform, with U.S. affiliate assets reaching approximately $2 trillion in 2021.
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc DiseaseSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Organovo Provides Business UpdateSAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business update.
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanySAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (
NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025.
Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining MomentumEnveric Biosciences (
NASDAQ: ENVB) Secures Patent for EVM401 Series, Advancing Neuropsychiatric Treatments Small-cap biotech stocks continue to push boundaries, with Enveric Biosciences (
NASDAQ: ENVB) securing U.S. Patent No. 12,195,439 for its EVM401 Series, a novel class of non-hallucinogenic mescaline derivatives designed for addiction and neuropsychiatric disorders . This milestone solidifies Enveric’s standing in the neuroplastogen therapeutics sector, a rapidly emerging field within mental health treatment. The EVM401 compounds exhibit unique brain receptor modulation, potentially offering new alternatives for patients with limited therapeutic options.
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and CompanySAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly and Company (
NYSE:LLY) (“Lilly”) will acquire Organovo’s FXR program, including its lead asset, FXR314.
In 2025, the pharmaceutical industry is ripe for M&ANow that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment for mergers and acquisitions
Maxwell Biosciences Announces Appointment of José Antonio Alas to Its Board of DirectorsAustin, Texas--(Newsfile Corp. - January 22, 2025) - Maxwell Biosciences ("Maxwell"), a pre-clinical drug platform company that develops Claromers™, ...
Soricimed Biopharma Appoints Dr. Neil Fleshner as Executive Board MemberMoncton, New Brunswick, Canada--(Newsfile Corp. - January 13, 2025) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage biopharmaceutical company focused on...
LeapFrog Investments raises more than $1 billion for impact health investingLeapFrog Investments said this week it has raised more than $1 billion in a new investment fund that targets high-impact health and financial-services
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform
Can Roche Challenge Lilly and Novo in the Weight Loss Market?One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on TopEli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.
Top 3 Stocks with Explosive Call Option Activity: What to WatchThree stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could SoarSkye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth.
3 Momentum Trades Too Good Pass UpCheck out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost CognitionNetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (“FDA”) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer’s. However, there is no molecule or a combination of molecules that enhance cognitive functions. Thanks to innovative approaches by companies such as Annovis Bio Inc. (
NYSE: ANVS) ( profile ), there is reason to be optimistic about potential future breakthroughs in the AD space. Annovis has completed early research with compelling results utilizing its lead drug, buntanetap, in combination with popular drugs approved for other indications. Broadly speaking, there is ample reason to be bullish on new treatments for a variety of significant diseases, including AD and obesity, as companies such as Eli Lilly (
NYSE: LLY) , Pfizer Inc. (
NYSE: PFE) , Novo Nordisk (
NYSE: NVO) and AbbVie Inc. (
NASDAQ: ABBV) are making investments and progress on historically…
